Immix Biopharma (IMMX) Completes $5M At-The-Market Program Jun 14, 2023 07:30AM
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program Jun 14, 2023 07:30AM
Nexcella, Inc. in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloi Dec 14, 2022 08:05AM
Nexcella, Inc. in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloi Dec 14, 2022 08:05AM
Immix Biopharma (IMMX) in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma and AL Amyloidosis Dec 14, 2022 08:04AM


Dec 14, 2022 08:00AM Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amylo
Dec 14, 2022 08:00AM Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amylo
Oct 25, 2022 08:00AM Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26
Dec 20, 2021 04:16PM Immix Biopharma, Inc. Announces Closing of Initial Public Offering
Dec 20, 2021 04:16PM Immix Biopharma, Inc. Announces Closing of Initial Public Offering
Dec 16, 2021 11:32AM Immix Biopharma (IMMX) IPO Opens Flat
Dec 16, 2021 06:13AM Immix Biopharma (IMMX) Prices 4.2M Share IPO at $10/sh
Dec 15, 2021 05:59PM Immix Biopharma, Inc. Announces Pricing of Initial Public Offering
Dec 15, 2021 05:59PM Immix Biopharma, Inc. Announces Pricing of Initial Public Offering
Sep 17, 2021 06:08AM Immix Biopharma (IMMX) Files for Up to 24.75M Share IPO